NOVONIX Limited filings document foreign-issuer reporting for an ADR-listed battery materials and technology company. Its Form 6-K reports furnish ASX announcements, operating and financial results, material-event disclosures, material agreements, shareholder voting matters, and governance updates.
Company filings also record capital-structure activity such as applications for quotation of ordinary fully paid shares, notifications of unquoted equity securities, employee incentive performance rights, and director interest notices. These disclosures connect NOVONIX's public reporting with its ordinary shares, American depositary shares, incentive securities, and governance obligations as an Australian issuer with U.S. reporting.
NOVONIX Limited reports that the ASX has granted waivers from Listing Rules 7.1 and 10.11 for its Share Purchase Plan. These waivers allow NOVONIX to issue new SPP shares at an offer price of $0.16 per share without prior shareholder approval and without using its standard placement capacity.
The offer price is the same as the institutional placement completed earlier and represents a discount of about 31.2% to the 5-day VWAP calculated to 15 June 2026. The company expects overall dilution from the SPP to be approximately 2.17%, with SPP shares capped at no more than 30% of existing fully paid ordinary shares.
The SPP timetable runs from a record date on 16 June 2026, opens on 22 June 2026, closes on 14 August 2026, with allotment on or about 19 August 2026 and trading of SPP shares expected to commence on or about 20 August 2026.
NOVONIX LIMITED has applied to quote 34,824 additional ordinary fully paid shares on the ASX, issued on July 3, 2026 after performance rights were converted under an employee incentive scheme. These new shares are valued at an estimated AUD 0.155 per security and rank equally with existing shares.
Following this small non-cash issuance, the company’s total quoted ordinary share capital will comprise 991,596,744 NVX ordinary fully paid shares. NOVONIX also has several classes of unquoted securities on issue, including performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd Chief Financial Officer Robert Buell Long reported internal changes to his equity awards involving performance rights. On June 30, 2026, three transactions coded as “J” (Other acquisition or disposition) affected a total of 4,576,670 performance rights tied to ordinary shares, all at a reported price of $0.00 per right. Each line shows zero performance rights remaining of that series following the transactions, and no ordinary share purchases or sales were reported.
NOVONIX Limited has detailed the pay package for Ron Edmonds as Interim Chief Financial Officer. His interim term runs for 3–6 months from 1 July 2026.
Mr Edmonds will receive a USD$450,000 base salary, pro‑rated for an expected 75% workload, plus a short‑term incentive of up to 100% of fixed pay based on Board‑set performance targets. He is also eligible for additional Director share rights valued at USD$95,000, subject to shareholder approval.
He remains a director but has stepped aside as Chair while serving as Interim CFO. Deputy Chair Admiral Robert Natter has resumed the role of Chair for the interim period, and the arrangements will continue until a permanent CFO is appointed or his interim role ends earlier.
NOVONIX Limited reported a change to its share capital after certain employee-style awards lapsed. On 30 June 2026, a total of 5,781,507 NVXAD PERFORMANCE RIGHTS ceased due to the lapse of conditional rights where vesting conditions were not, or could not be, satisfied. The company confirmed it paid no consideration for this cessation.
After this change, NOVONIX’s issued capital includes 991,561,920 NVX ordinary fully paid shares on issue and unquoted equity securities such as 21,619,875 NVXAD performance rights, 14,016,667 NVXAA options, 1,371,566 NVXAB share rights and 45,221,586 NVXAL convertible notes.
NOVONIX Limited has launched a Share Purchase Plan (SPP) giving eligible Australian and New Zealand shareholders the option to buy additional shares at a discounted price. The company aims to raise about A$3.0 million through the SPP at an issue price of A$0.16 per share.
Each eligible holder can apply for parcels of up to A$30,000 in new shares without brokerage, with pricing set at a 33.3% discount to the A$0.24 closing price on 15 June 2026 and a 31.2% discount to the five‑day VWAP to that date. The SPP follows an institutional placement that raised approximately A$20.7 million, with combined proceeds earmarked for capital expenditure to expand production capacity and meet forecast customer demand.
Novonix Limited has applied to quote 129,334,163 new ordinary fully paid shares on the ASX. These shares were issued as part of a previously announced placement and are priced at AUD 0.16 per share, with an issue date of June 22, 2026.
After quotation, Novonix will have 991,561,920 ordinary shares on issue. The company also has unquoted instruments on issue, including 27,401,382 performance rights, 14,016,667 options, 1,371,566 share rights, 45,221,586 convertible notes and 35,000,000 convertible debentures, which together outline additional potential equity overhang.
NOVONIX Limited is raising new equity through an institutional placement and a discounted share purchase plan. The company received firm commitments for approximately A$20.7 million via an Institutional Placement of 129,334,163 fully paid ordinary shares at A$0.16 per share, using its remaining 15% placement capacity under ASX Listing Rule 7.1.
In parallel, NOVONIX is launching a Share Purchase Plan (SPP) allowing eligible Australia and New Zealand shareholders to apply for up to A$30,000 of shares each, at the same A$0.16 offer price, with a maximum of 18,750,000 SPP shares and an expected raise of approximately A$3.0 million if fully subscribed.
The offer price represents a 33.3% discount to the last traded price of A$0.24 on 15 June 2026 and a 31.2% discount to the five-day VWAP of A$0.23. Proceeds are expected to fund capital expenditure to expand production capacity and support forecast customer demand. A trading halt was requested on 16 June 2026 ahead of the capital raising announcement.
NOVONIX Limited reported a key operational milestone, delivering a mass production qualification “C-sample” of synthetic graphite anode active material to its lead customer, Panasonic Energy. The company says internal testing shows the material meets Panasonic’s required specifications, while formal validation will depend on Panasonic’s assessment in the coming months.
The delivery is described as the first known Synthetic Graphite AAM C-sample produced in North America and is framed as an important step toward a secure U.S. battery materials supply chain. NOVONIX also reaffirmed its expectation that mass production for Panasonic will begin in the second half of 2027, subject to successful completion of qualification by Panasonic and its customers.
NOVONIX Limited reports a leadership transition in its finance team. Chief Financial Officer Robert Long will leave the company in July to pursue other opportunities. Current Chair Ron Edmonds, a veteran finance leader formerly with Dow Chemical, will serve as Interim Chief Financial Officer and step aside as Chair during the search for a permanent replacement. Deputy Chair Admiral Robert Natter will take over as Chair so Edmonds can focus on the interim CFO role. The Board states it is confident these arrangements will maintain leadership continuity and support ongoing operations while a new full-time CFO is recruited.